Humacyte, Inc. (NASDAQ:HUMA) is identified as one of the Best Micro-Cap Stocks to Invest in According to Analysts. Benchmark analyst Bruce Jackson maintained a Buy rating on HUMA stock with a price target of $11. The company develops bioengineered human tissues for various diseases and conditions.

Humacyte, Inc. (NASDAQ:HUMA) recently announced a $60 million securities purchase agreement with institutional investors for its common stock and warrants. The oversubscribed offering includes warrants that become exercisable 180 days after issuance with an exercise price of $2.11 per share.

While HUMA is seen as a potential investment, some believe that certain AI stocks offer greater upside potential with less downside risk. For those interested in an undervalued AI stock benefiting from current trends, a free report is available on the best short-term AI stock.

For more investment opportunities, check out 15 Dividend Stocks Paying 4%+ Yield in 2025 and 14 Best US Stocks to Buy for the Long Term. Disclosure: None.

Read more at Yahoo Finance: Benchmark Remains Bullish on Stock